2011-09-09Zeitschriftenartikel DOI: 10.1371/journal.pone.0023946
Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort.
Lunzen, Jan van
Background/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a longterm follow-up of direct costs for combined antiretroviral therapy, cART,-regimens in the nationwide long-term observational multi-centre German HIV ClinSurv Cohort. The second aim was to develop potential cost saving strategies by modelling different treatment scenarios. Methods: Antiretroviral regimens (ART) from 10,190 HIV-infected patients from 11 participating ClinSurv study centres have been investigated since 1996. Biannual data cART,-initiation, cART-changes, surrogate markers, clinical events and the Centre of Disease Control- (CDC)-stage of HIV disease are reported. Treatment duration was calculated on a daily basis via the documented dates for the beginning and end of each antiretroviral drug treatment. Prices were calculated for each individual regimen based on actual office sales prices of the branded pharmaceuticals distributed by the license holder including German taxes. Results: During the 13-year follow-up period, 21,387,427 treatment days were covered. Cumulative direct costs for antiretroviral drugs of J812,877,356 were determined according to an average of J42.08 per day (J7.52 to J 217.70). Since cART is widely used in Germany, the costs for an entire regimen increased by 13.5%. Regimens are more expensive in the advanced stages of HIV disease. The potential for cost savings was calculated using non-nucleotide-reverse-transcriptaseinhibitor, NNRTI, more frequently instead of ritonavir-boosted protease inhibitor, PI/r, in first line therapy. This calculation revealed cumulative savings of 10.9% to 19.8% of daily treatment costs (50% and 90% substitution of PI/r, respectively). Substituting certain branded drugs by generic drugs showed potential cost savings of between 1.6% and 31.8%. Conclusions: Analysis of the data of this nationwide study reflects disease-specific health services research and will give insights into the cost impacts of antiretroviral therapy, and might allow a more rational allocation of resources within the German health care system.
No license information
Show related Items with similar Title, Author, Creator or Subject.
2014-04-10ZeitschriftenartikelPatterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group Frentz, Dineke; Vijver, David van de; Abecasis, Ana B.; Albert, Jan; Hamouda, Osamah; Jørgensen, Louise; Kücherer, Claudia; Struck, Daniel; Schmit, Jean-Claude; Vercauteren, Jurgen; Åsjö, Birgitta; Balotta, Claudia; Bergin, Colm; Beshkov, Danail; Camacho, Ricardo; Clotet, Bonaventura; Griskevicius, Algirdas; Grossman, Zehava; Horban, Andrzej; Kolupajeva, Tatjana; Korn, Klaus; Kostrikis, Leondios; Liitsola, Kirsi; Nielsen, Claus; Otelea, DanBackground: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to ...
2011-09-01ZeitschriftenartikelInfluenza Virus Ribonucleoprotein Complexes Gain Preferential Access to Cellular Export Machinery through Chromatin Targeting Chase, Geoffrey P.; Rameix-Welti, Marie-Anne; Zvirbliene, Aurelija; Zvirblis, Gintautas; Götz, Veronika; Wolff, Thorsten; Naffakh, Nadia; Schwemmle, MartinIn contrast to most RNA viruses, influenza viruses replicate their genome in the nucleus of infected cells. As a result, newly-synthesized vRNA genomes, in the form of viral ribonucleoprotein complexes (vRNPs), must be ...
2009-04-01ZeitschriftenartikelOseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season Meijer, Adam; Lackenby, Angie; Hungnes, Olav; Lina, Bruno; Werf, Sylvie van der; Schweiger, Brunhilde; Opp, Matthias; Paget, John; Kassteele, Jan van de; Hay, Alan; Zambon, Maria; Buchholz, Udo; Haas, WalterIn Europe, the 2007-08 winter season was dominated by influenza virus A (H1N1) circulation through week 7, followed by influenza B virus from week 8 onward. Oseltamivir-resistant influenza viruses A (H1N1) (ORVs) with H275Y ...